New Research on Beneficial Combination of Alpha Lipoic Acid and Omega-3 Fatty Acids for Alzheimer’s Disease Announced by Ethical Alternative Products

January 30, 2014

A randomized placebo-controlled pilot trial using a combination of omega-3 fatty acids and alpha lipoic acid to treat mild to moderate Alzheimer’s disease, yielded promising results demonstrating that the combination of omega-3’s and alpha lipoic acid slowed cognitive and functional decline in AD over 12 months.

Wyckoff, NJ (PRWEB) January 30, 2014

Oxidative stress, inflammation, and increased cholesterol levels are all mechanisms that have been associated with Alzheimer’s disease (AD) pathology, and provide the basis for evaluation of dietary interventions with fish oils and antioxidants. A study was undertaken by Shinto L.* et al. at Oregon Health & Science University, to determine if the reported benefits of fish oil supplementation could be enhanced by co-administration of alpha lipoic acid, with its added beneficial effects on oxidative stress. A reduction in oxidative stress bio-markers was not realized in the study, but the combination did slow cognitive decline and functional decline, suggesting a mechanism other than oxidative stress was responsible for the favorable outcomes.

The study employed the Mini-Mental State Examination (MMSE) to measure cognitive ability, and observed no difference between placebo and omega-3 treatment, but there was a significant difference between placebo and the omega-3 and alpha lipoic acid combination group, suggesting that the combination therapy decreased the rate of decline in MMSE over 12 months. Using Activities of Daily Living/Instrumental Activities of Daily Living (ADL/IADL) as the measure of functional ability the study showed less decline in IADL over 12 months for the omega-3 group and the combination group compared to placebo.

The authors conclude that "in this small pilot study combining omega-3 with alpha lipoic acid slowed both cognitive and functional decline in mild to moderately impaired AD participants over 12 months, and the combination appears to be safe at the doses evaluated. Because the results are derived from a small sample size, caution in broadly interpreting the outcomes reported is warranted. A larger pilot trial is underway to further assess the benefit and potential mechanism of action of this novel combination for AD."

Ethical Alternative Products supplies alpha lipoic acid in a premium high bioavailability formulation marketed under the ThioGel brand. ThioGel is a high performance product that is formulated with raw material alpha lipoic acid that is sourced in Europe.

About Ethical Alternative Products

Ethical Alternative Products is a dietary supplement supplier that is focused on the formulation of scientifically sound natural products that can make a meaningful difference in achieving and maintaining health during aging. The mission of our senior scientific management is to develop and produce high-value supplements, employing innovative formulations and highest quality raw materials. Products produced by Ethical Alternative Products include ThioGel liquid gel alpha lipoic acid, ThioGel-L triple antioxidant liver formulation, OmniFlex multi-nutrient joint health product and Tendonex topical pain reliever. antioxidant liver formulation, OmniFlex multi-nutrient joint health product and Tendonex topical pain reliever.

  • A Randomized Placebo-Controlled Pilot Trial of Omega-3 Fatty

Acids and Alpha Lipoic Acid in Alzheimer’s Disease

Lynne Shinto,* Joseph Quinn, Thomas Montine, Hiroko H. Dodge, William

Woodward, Sara Baldauf-Wagner, Dana Waichunas, Lauren Bumgarner, Dennis

Bourdettea, Lisa Silbert, and Jeffrey Kaye

J Alzheimers Dis. 2014 ; 38(1):10.3233/JAD-130722.


For the original version on PRWeb visit: http://www.prweb.com/releases/2014/01/prweb11537856.htm

Source: prweb

comments powered by Disqus